Literature DB >> 20690508

Belgian and European experience with the European Homograft Bank (EHB) cryopreserved allograft valves.--assessment of a 20 year activity.

R Jashari1, Y Goffin, B Van Hoeck, A Vanderkelen, A du Verger, Y Fan, V Holovska, A Fagu, O Brahy.   

Abstract

European Homograft Bank (EHB) has been selecting, preparing, storing and distributing the cryopreserved allograft valves in Belgium and some other European Countries since 1989. It was established in 1988 by a pathologist and the cardiac and vascular surgeons from Belgian and other European centres as an inter-university, international nonprofit association. Due to its neutral behavior and very high quality criteria, European Homograft Bank became one of the prominent heart valve banks in Europe and wider. It collaborates with the transplant coordination in donor selection as well as with the huge network of the implanting surgeons in Belgium and other European Countries. The EHB responsible discusses with the implanting surgeon the allograft selection on basis of the indication and the patients state of emergency. A total of 8.911 donor heart valves have been evaluated in EHB during the last 20 years. After selection, 5.258 allograft valves (1.996 aortic, 3.189 pulmonary and 73 mitral) were cryopreserved and stored in vapors of liquid nitrogen between 6 weeks and 5 years. A total of 4.516 allograft valves (1.391 aortic, 2.620 pulmonary and 48 mitral) were implanted in the left or right ventricular outflow tract for replacement of the diseased aortic or pulmonary valve and for mitral or tricuspid valve replacement or repair. In 1.380 cases the allograft valves were used for right ventricular outflow tract reconstruction as part of the Ross- procedure, whereas in 668 cases the allograft valve served for replacement of the aortic valve for endocarditis. The most important indications for use of cryopreserved allograft valves were: important cardiac and valve malformation in children, female patients of child-bearing age with diseased cardiac valves, cases with contra-indication for anti-coagulation and the patients with severe endocarditis with septal or annular abscesses. Although the number of the donation increased by year, the available allograft valves in stock are still insufficient to respond to all the surgeons' request for different indications.

Entities:  

Mesh:

Year:  2010        PMID: 20690508     DOI: 10.1080/00015458.2010.11680618

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  3 in total

1.  Decellularized aortic conduits: could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts.

Authors:  Michele Gallo; Antonella Bonetti; Helen Poser; Filippo Naso; Tomaso Bottio; Roberto Bianco; Adolfo Paolin; Paolo Franci; Roberto Busetto; Anna Chiara Frigo; Edward Buratto; Michele Spina; Maurizio Marchini; Fulvia Ortolani; Laura Iop; Gino Gerosa
Journal:  Heart Vessels       Date:  2016-04-26       Impact factor: 2.037

2.  Homograft Versus Valves and Valved Conduits for Extensive Aortic Valve Endocarditis with Aortic Root Involvement/Destruction: A Systematic Review and Meta-Analysis.

Authors:  Michael L Williams; John D L Brookes; Joseph S Jaya; Eren Tan
Journal:  Aorta (Stamford)       Date:  2022-08-07

3.  Cryopreserved human heart valve allografts: a ten-year single centre experience.

Authors:  Marijana Skific; Mirna Golemovic; Ivica Safradin; Zeljko Duric; Bojan Biocina; Branka Golubic Cepulic
Journal:  Cell Tissue Bank       Date:  2022-10-12       Impact factor: 1.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.